Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Kreipke says that previous drugs to target blood vessel constriction have caused the vessels to dilate too much, which can put a patient at risk of bleeding. Clazosentan, he says, has a more specific action—it blocks a receptor in cells called endothelin receptor A, which is involved in vessel constriction. “This drug doesn’t cause more blood flow,” he says—it just decreases the severity of the drop in flow.

Ross Zafonte, a TBI expert at Spauding Rehabilitation Hospital in Boston, says the concept of targeting blood flow abnormalities in TBI is promising, and adds that this drug, with its specific molecular target, is a “more refined and elegant variant” on this strategy. But he cautions that many TBI treatments developed over the years “have looked good in the laboratory,” including in rodent tests, “yet very few things have been shown to be helpful in humans.”

Clazosentan, which is manufactured by Swiss company Actelion Pharmaceuticals, has recently been investigated as a treatment for brain hemorrhage, but clinical trial results have been disappointing. Kreipke has higher hopes for its efficacy in TBI. Because the drug has already been through safety testing in humans, he hopes to move ahead soon with a clinical trial for patients with moderate to severe TBI.

0 comments about this story. Start the discussion »

Tagged: Biomedicine, military, brain injury, TBI, blood vessels

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me